Tags

Type your tag names separated by a space and hit enter

Bisphosphonates and metastatic breast carcinoma.
Cancer. 2003 Feb 01; 97(3 Suppl):848-53.C

Abstract

BACKGROUND

Metastasis to the skeleton occurs in approximately 75% of patients with advanced breast cancer. It is the cause of much morbidity and decreased quality of life in these patients.

METHODS

Zoledronic acid (Zoledronate) is a new, potent third-generation bisphosphonate that has recently been approved by the U.S. Food and Drug Administration for the treatment of both osteolytic and osteoblastic bone metastases. A Phase 3 clinical trial comparing the efficacy of Zoledronic acid 4 and 8 mg compared with Pamidronate 90 mg every 3-4 weeks has been completed.

RESULTS

A 15 minute infusion of 4 mg of zoledronic acid is at least as effective as 90 mg of pamidronate in preventing skeletal complications in patients with metastatic breast cancer.

CONCLUSIONS

Bisphosphonate treatment can delay skeletal events in patients with breast carcinoma that is metastatic to bone. Future trials will build on the results achieved with bisphosphonate treatment.

Authors+Show Affiliations

Division of Hematology/Oncology, Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, USA. Alipton@psu.edu

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Review

Language

eng

PubMed ID

12548585

Citation

Lipton, Allan. "Bisphosphonates and Metastatic Breast Carcinoma." Cancer, vol. 97, no. 3 Suppl, 2003, pp. 848-53.
Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer. 2003;97(3 Suppl):848-53.
Lipton, A. (2003). Bisphosphonates and metastatic breast carcinoma. Cancer, 97(3 Suppl), 848-53.
Lipton A. Bisphosphonates and Metastatic Breast Carcinoma. Cancer. 2003 Feb 1;97(3 Suppl):848-53. PubMed PMID: 12548585.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bisphosphonates and metastatic breast carcinoma. A1 - Lipton,Allan, PY - 2003/1/28/pubmed PY - 2003/4/15/medline PY - 2003/1/28/entrez SP - 848 EP - 53 JF - Cancer JO - Cancer VL - 97 IS - 3 Suppl N2 - BACKGROUND: Metastasis to the skeleton occurs in approximately 75% of patients with advanced breast cancer. It is the cause of much morbidity and decreased quality of life in these patients. METHODS: Zoledronic acid (Zoledronate) is a new, potent third-generation bisphosphonate that has recently been approved by the U.S. Food and Drug Administration for the treatment of both osteolytic and osteoblastic bone metastases. A Phase 3 clinical trial comparing the efficacy of Zoledronic acid 4 and 8 mg compared with Pamidronate 90 mg every 3-4 weeks has been completed. RESULTS: A 15 minute infusion of 4 mg of zoledronic acid is at least as effective as 90 mg of pamidronate in preventing skeletal complications in patients with metastatic breast cancer. CONCLUSIONS: Bisphosphonate treatment can delay skeletal events in patients with breast carcinoma that is metastatic to bone. Future trials will build on the results achieved with bisphosphonate treatment. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/12548585/Bisphosphonates_and_metastatic_breast_carcinoma_ L2 - https://doi.org/10.1002/cncr.11123 DB - PRIME DP - Unbound Medicine ER -